• 2. November 2024

Merus starts Phase I/II clinical trial for MCLA-128, an ADCC-enhanced bispecific antibody for solid tumors

ByMerus B.V.

Feb 4, 2015
– First patient dosed in trial with potent bispecific antibody overcoming resistance to HER2-targeted therapies –
Teile den Beitrag mit Freunden

Kommentar verfassen